U-47700

U-47700 is a synthetic opioid from the benzamide family. It was developed by the Upjohn Company in the 1970s during research into analgesic compounds, but was never approved as a medicine. Decades later it appeared on illicit drug markets, sometimes sold as a heroin or prescription-opioid substitute. U-47700 is a potent μ-opioid receptor agonist and has been associated with numerous non-fatal intoxications and fatal overdoses.

Chemistry and history

U-47700 is 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide. It is a structural isomer of AH-7921 and belongs to the non-fentanyl synthetic opioid group. The molecule has two chiral centres, producing four possible stereoisomers; the pharmacological properties can differ between these forms.

The compound first became visible on recreational markets in the United States around 2014. It was sold online as a research chemical and was also found in counterfeit tablets and mixed illicit products. The WHO reviewed U-47700 in 2016 and recommended international control because of its abuse potential, lack of recognised therapeutic use and association with fatal intoxications (WHO Expert Committee on Drug Dependence: U-47700 critical review).

Pharmacology

U-47700 acts primarily as an agonist at the μ-opioid receptor (MOR), with activity also reported at the δ-opioid receptor. Preclinical studies found potent antinociceptive effects, with approximately 7.5 times the potency of morphine in a mouse behavioural test. A reported human MOR binding affinity is in the low-nanomolar range (DARK Classics in Chemical Neuroscience: U-47700, 2020).

Its opioid mechanism resembles that of morphine and other μ-opioid agonists. The principal danger is respiratory depression, which can progress to hypoxia, unconsciousness and death. The absence of fentanyl-like chemical structure does not make U-47700 less dangerous.

Clinical effects and overdose

Reported intoxications resemble an opioid toxidrome. Clinical signs include pinpoint pupils, reduced level of consciousness, slow or ineffective breathing, cyanosis and bradycardia. The WHO review notes that respiratory depression and depressed consciousness may respond to naloxone, as with other opioid poisonings (WHO critical review of U-47700).

Fatal cases have frequently involved pulmonary oedema, sometimes alongside other opioids, benzodiazepines or new psychoactive substances. The combination of respiratory depression and uncertain product composition makes the clinical course difficult to predict.

Clinical and forensic findings

A clinical review identified 16 patients across ten published reports. Patients who died after overdose commonly presented with pulmonary oedema, and the review found no clinical trial data establishing the safety of U-47700 (U-47700: A Clinical Review of the Literature, 2017).

A German forensic study examined 26 fatalities between 2016 and 2017. U-47700 was considered the cause of death either alone or in combination with other psychoactive substances. In 15 cases, additional new psychoactive substances were also detected (Post-mortem concentrations of U-47700 in 26 fatalities, 2019).

A broader review of U-47700 and its analogues summarises numerous intoxications and deaths and emphasises the difficulty of interpreting cases involving counterfeit tablets and polydrug exposure (U-47700 and its analogues: non-fentanyl synthetic opioids, 2020).

Dependence and research limitations

Controlled studies of dependence potential in humans or animals were not available to the WHO review. However, reports from users described tolerance and withdrawal symptoms after discontinuation, which are consistent with physical opioid dependence. These reports are not a substitute for controlled clinical research.

Human pharmacokinetic data remain limited, and post-mortem concentrations vary widely. Co-exposure to fentanyl, heroin, benzodiazepines and other depressants can increase the risk of fatal respiratory depression and make it harder to identify each substance’s contribution.

Regulatory status

The WHO recommended that U-47700 be placed in Schedule I of the 1961 Single Convention on Narcotic Drugs. It is controlled internationally and has no recognised therapeutic use or approved medicinal product history (WHO ECDD recommendation).

Related compounds

U-47700 is related to AH-7921, U-48800 and other non-fentanyl synthetic opioids. It is a benzamide opioid and should not be confused with fentanyl analogues, which belong to a different chemical family.